Introduction
============

In 2013, stroke was the second leading cause of death (11.8% of all deaths) worldwide following ischemic heart disease (14.8% of all deaths) \[[@b1-jos-2017-02810]\]. According to the 2013 Global Burden of Disease study, the incidence, mortality, and disability-adjusted life years lost to ischemic stroke were on a declining trend from 1990 to 2013 \[[@b2-jos-2017-02810]\]. However, the overall stroke burden, which is the absolute number of individuals affected by stroke or those who remained disabled from stroke, has increased in both sexes of all ages worldwide \[[@b1-jos-2017-02810],[@b2-jos-2017-02810]\]. Therefore, to reduce this overall stroke burden, the management of common modifiable lifestyle risk factors (e.g., smoking, unhealthy diet, physical inactivity, and harmful use of alcohol) is the first priority. Further, the control of other major risk factors, such as hypertension and atrial fibrillation (AF), effective treatment in the acute phase, and rehabilitation and long-term follow-up for secondary prevention are important. In addition, it is necessary to make an effort to find unconventional risk factors and control them adequately.

Heart failure (HF) is also a global major cause of death and is a rapidly growing public health issue affecting approximately 40 million individuals worldwide \[[@b3-jos-2017-02810]\]. HF and stroke commonly coexist and share common risk factors, including AF. Although the risk of ischemic stroke is two to three times higher in patients with HF than in those without \[[@b4-jos-2017-02810]-[@b6-jos-2017-02810]\], whether HF itself accounts for the high risk remains unclear because most studies regarding stroke in HF did not differentiate between patients with and without AF nor completely adjust for the confounding variables.

In this review, we provide an up-to-date overview of the relationship between stroke and HF, which could be an unconventional risk factor and a potential intervention target for stroke prevention \[[@b7-jos-2017-02810]-[@b9-jos-2017-02810]\].

What is HF and why is it important?
===================================

Definition of HF
----------------

HF is a comprehensive concept that covers the chronic phase of a multitude of cardiac diseases \[[@b7-jos-2017-02810]\]. The current European Society of Cardiology guideline defined HF as a clinical syndrome with typical symptoms (e.g., dyspnea, ankle swelling, and fatigue) that may be accompanied by signs (e.g., elevated jugular venous pressure, pulmonary crackles, and peripheral edema) caused by a structural and/or functional cardiac abnormality, resulting in a reduced cardiac output and/or elevated intracardiac pressures at rest or during stress \[[@b8-jos-2017-02810]\]. In addition to typical symptoms or signs, early measurement of the plasma natriuretic peptide level and echocardiography are used to diagnose and classify HF. According to the guideline, HF with reduced ejection fraction (HFrEF) is defined as an ejection fraction of \<40% (previously referred to as "systolic HF"), whereas HF with preserved ejection fraction (HFpEF) is defined as an ejection fraction of ≥50% (previously referred to as "diastolic HF"). Patients with an ejection fraction in the range of 40% to 49% are considered to have HF with mid-range ejection fraction (HFmrEF).

HF typically develops as a result of several health problems related to congenital or acquired conditions and not a single illness. The major risk factors for HF are hypertension, coronary artery disease, valvular heart disease, diabetes, and AF \[[@b9-jos-2017-02810]\].

Because a failing heart cannot provide sufficient blood and oxygen to the body to ensure systemic metabolism at rest and during activity, when organ perfusion is confined to the brain, HF may cause cerebral ischemia and stroke.

Epidemiology and clinical significance of HF
--------------------------------------------

Approximately 40.0 million individuals are living with HF worldwide \[[@b3-jos-2017-02810]\]. As of 2011 in the United States, there are approximately 5.7 million patients with HF, and approximately 870,000 patients are newly diagnosed with HF \[[@b10-jos-2017-02810]\]. It has been reported that 1% to 2% of the population has HF, and the prevalence increases with age \[[@b11-jos-2017-02810]\]. The prevalence rate is \<1% in individuals under 40 years of age, but is \>10% in those over 80 years of age, and generally doubles in each decade of life \[[@b10-jos-2017-02810]\]. Therefore, the number of patients with HF is expected to increase as the population ages. In addition, decreased mortality owing to recent therapeutic improvement of cardiovascular disease may paradoxically increase the number of patients at risk of developing HF. Moreover, patients with HF have a high rate of re-hospitalization (44% within 1 year of discharge) \[[@b12-jos-2017-02810]\] and mortality (\~20% after 1 year and \~50% after 5 years) \[[@b7-jos-2017-02810]\]. The mortality rate of HF is higher than that of most cancers \[[@b13-jos-2017-02810]\]. Therefore, managing patients with HF is important in reducing social and economic burden as well as medical burden.

Relationship between HF and neurologic diseases
===============================================

Stroke
------

### Prevalence of stroke in patients with HF: the rate of stroke increased significantly in HF

Previous studies showed that approximately 10% to 24% of patients with stroke have HF \[[@b14-jos-2017-02810]-[@b17-jos-2017-02810]\], and HF appears to be the cause of stroke in 9% of the patients \[[@b18-jos-2017-02810],[@b19-jos-2017-02810]\]. Patients with stroke and HF have higher mortality rates, more severe neurologic deficits, and longer hospital stays than those without HF \[[@b19-jos-2017-02810]\]. According to the Framingham study \[[@b5-jos-2017-02810]\], the risk of ischemic stroke was two to three times higher in patients with HF than in those without HF, which was also supported by other community-based studies \[[@b4-jos-2017-02810],[@b6-jos-2017-02810]\]. Recently, a population-based cohort study reported that patients with HF had a higher risk of all subtypes of stroke, as well as ischemic stroke, than the general population \[[@b20-jos-2017-02810]\]. These results suggest that there is no doubt that the risk of stroke is increased in patients with HF. However, as HF is often accompanied by traditional risk factors for stroke, such as hypertension, coronary artery disease, AF, diabetes mellitus, and obesity \[[@b21-jos-2017-02810]\], it remains controversial that HF itself is an independent stroke risk factor \[[@b4-jos-2017-02810],[@b22-jos-2017-02810]-[@b27-jos-2017-02810]\]. Nevertheless, a recent 30-year population-based cohort study demonstrated a significant relationship between HF and short-term and long-term risks of all stroke subtypes even after adjustment for a range of confounders, including AF or atrial flutter \[[@b20-jos-2017-02810]\].

### HF with AF

Untreated AF can cause ventricular dysfunction via tachycardia-induced cardiomyopathy and promote deterioration in preexisting HF with loss of atrial contraction for ventricular filling \[[@b28-jos-2017-02810]\]. Patients with HF are also more likely to develop AF owing to changes in hemodynamics (i.e., pressure and volume overload) and cellular changes, such as fibrosis and/or automaticity, in association with shared risk factors, such as hypertension, age, diabetes, metabolic syndrome, and arteriosclerosis \[[@b29-jos-2017-02810]\]. Although HF and AF can occur independently, the prevalence of HF and AF increases further in the presence of each other, and these two entities often co-exist in the same population \[[@b29-jos-2017-02810],[@b30-jos-2017-02810]\]. According to the Framingham Heart Study, AF occurred in more than half (57%) of the individuals with HF, and HF occurred in over one-thirds (37%) of the individuals with AF \[[@b31-jos-2017-02810]\]. Patients with HF and AF are more prone to develop stroke and had a 5-fold increased risk than the control population \[[@b32-jos-2017-02810]\]. A recent meta-analysis showed that there was no difference between patients with AF with HFpEF and HFrEF in terms of stroke risk, although the all-cause mortality rate was significantly higher in the latter than in the former \[[@b33-jos-2017-02810]\]. Interestingly, Mogensen et al. \[[@b34-jos-2017-02810]\] reported that the type of AF (paroxysmal, persistent or permanent, or new-onset) may be associated with the stroke risk in patients with HFrEF. In this study, persistent or permanent AF did not increase the stroke risk; however, paroxysmal (hazard ratio \[HR\], 1.34; 95% confidence interval \[CI\], 1.02 to 1.76) and new-onset (HR, 2.20; 95% CI, 1.25 to 3.88) AF significantly increased the risk when compared to the absence of AF.

### HF with sinus rhythm

There were only a few studies investigating the relationship between stroke and HF with sinus rhythm, and the results were limited by their small sample size, short-term follow-up, and other confounding factors, such as the incidence of AF and the use of HF medications as well as antithrombotics \[[@b4-jos-2017-02810]-[@b6-jos-2017-02810],[@b23-jos-2017-02810]\]. However, there has been a consensus that the risk of ischemic stroke, thromboembolism, and death increases in patients with HF even with sinus rhythm \[[@b35-jos-2017-02810]\], which is also consistent with the findings of several recent studies \[[@b20-jos-2017-02810],[@b32-jos-2017-02810],[@b36-jos-2017-02810],[@b37-jos-2017-02810]\].

Two population-based cohort studies recently demonstrated that patients with HF had an increased risk for ischemic stroke irrespective of AF when compared with the general population \[[@b20-jos-2017-02810],[@b32-jos-2017-02810]\]. Results from a Korean cohort showed that patients with HF but without AF had a 3.5-fold increased risk for stroke, while those with HF and AF demonstrated a \>5-fold increased risk for stroke \[[@b32-jos-2017-02810]\]. In particular, a multivariate analysis performed on a Danish cohort revealed that the risk of stroke in patients with HF was five times higher during the initial 30 days following incident HF hospitalization even after adjusting for matching factors, including AF \[[@b20-jos-2017-02810]\]. However, both studies did not differentiate between the HF types, HFrEF and HFpEF, and the diagnoses were based on ICD (International Classification of Diseases) codes \[[@b20-jos-2017-02810],[@b32-jos-2017-02810]\].

There were analyses of the risk for stroke according to the HF type and presence of AF using pooled data from existing HF randomized clinical trials ([Table 1](#t1-jos-2017-02810){ref-type="table"}) \[[@b36-jos-2017-02810],[@b37-jos-2017-02810]\]. Among patients with HFrEF, those without AF had a lower stroke risk than those with AF (1.2% per year vs. 1.6% per year, respectively) \[[@b37-jos-2017-02810]\]. Although patients with HFpEF but without AF also showed a lower stroke risk than those with AF (1.0% per year vs. 1.8% per year, respectively) \[[@b36-jos-2017-02810]\], the risk was still substantial and higher than that in the general population \[[@b32-jos-2017-02810]\]. However, even in the absence of AF, if patients with HF also presented with significant comorbidities of stroke, their stroke risk was comparable to that of patients with HF and AF \[[@b32-jos-2017-02810],[@b36-jos-2017-02810],[@b37-jos-2017-02810]\]. In addition, the overall stroke risk in patients without AF was similar to that in patients with HFpEF and HFrEF, although the risk was higher in patients with HFrEF than in those with HFpEF in high-stroke risk subgroups ([Table 1](#t1-jos-2017-02810){ref-type="table"}) \[[@b36-jos-2017-02810],[@b37-jos-2017-02810]\]. Nevertheless, a severely impaired left ventricular ejection fraction is a well-known risk factor for stroke \[[@b26-jos-2017-02810],[@b27-jos-2017-02810],[@b38-jos-2017-02810]\].

As will be described later, the mechanism of stroke in HF has mostly been studied in patients with HFrEF; however, data explaining this mechanism in patients with HFpEF remains limited. In patients with HFpEF, alterations in the cardiac structure, e.g., left ventricular hypertrophy or concentric remodeling and diffuse myocardial fibrosis, have been reported \[[@b39-jos-2017-02810]-[@b41-jos-2017-02810]\]. Increased myocardial stiffness due to these structural changes and left atrial enlargement may lead to blood stasis, which in turn contributes to stroke. In addition to these structural changes, prothrombotic trends are observed in HFpEF, which will also be described later.

### Left ventricular wall motion abnormality

Left ventricular wall motion abnormality (LVWMA) has been suggested as a low or an uncertain risk factor in terms of cerebral embolic risk \[[@b42-jos-2017-02810]\]. LVWMA is associated with regional blood stasis and incomplete ventricular emptying, which may increase thrombogenicity and induce intraventricular thrombus formation \[[@b43-jos-2017-02810]-[@b45-jos-2017-02810]\]. However, as LVWMA may be an epiphenomenon of underlying cardiac diseases, such as myocardial infarction or dilated cardiomyopathy, it is difficult to evaluate the risk of stroke for LVWMA itself.

A population-based study reported a strong correlation between LVWMA and cardiovascular events in adults without clinically evident cardiovascular disease \[[@b46-jos-2017-02810]\] (segmental LVWMA: HR, 2.5; 95% CI, 1.9 to 3.3; *P*\<0.0001 and global LVWMA: HR, 2.4; 95% CI, 1.4 to 4.1; *P*=0.001). The statistical power was weak; however, the risk of stroke increased by 1.7-fold (95% CI, 0.8 to 4.0; *P*=0.20) in the presence of segmental LVWMA and by 3.1-fold (95% CI, 1.0 to 9.8; *P*=0.06) in the presence of global LVWMA \[[@b46-jos-2017-02810]\]. In a recent observational study involving patients with stroke without high-risk cardioembolic conditions, such as myocardial infarct, dilated cardiomyopathy, and ejection fraction of \<30%, the presence of LVWMA was associated with any type of stroke (HR, 1.75; 95% CI, 1.29 to 2.36; *P*\<0.001) or ischemic stroke, specifically (HR, 1.70; 95% CI, 1.22 to 2.38; *P*=0.002) \[[@b47-jos-2017-02810]\]. Interestingly, in the subgroup analysis of this study, antithrombotic treatment, including anticoagulation, did not alter the effect of LVWMA on the recurrence of stroke. However, statin treatment reduced the effect of LVWMA on the stroke outcomes. Given the beneficial effect of statins on coronary artery disease \[[@b48-jos-2017-02810]\], atherosclerotic stroke \[[@b49-jos-2017-02810]\], and cardioembolic stroke \[[@b50-jos-2017-02810]\], it is necessary to evaluate unrecognized cardiac diseases, and at least statin treatment might be considered for stroke prevention in patients with LVWMA.

### "Silent" stroke in HF

The development of imaging technology has increased the prevalence of magnetic resonance imaging-detected silent stroke \[[@b19-jos-2017-02810]\]. An increased recognition of silent stroke might improve our understanding of the relationship between stroke and HF \[[@b51-jos-2017-02810]\]. Several studies have reported that silent stroke also occurs more frequently in patients with HF \[[@b52-jos-2017-02810]-[@b55-jos-2017-02810]\]. The independent risk factors associated with silent stroke in HF are as follows: (1) impaired left ventricular function; (2) restrictive diastolic filling patterns on echocardiography; (3) left atrial and aortic spontaneous echo contrast; and (4) complex or calcified atherosclerotic lesions in the aorta \[[@b51-jos-2017-02810],[@b52-jos-2017-02810],[@b56-jos-2017-02810]\]. Such silent stroke is often described as a precursor of symptomatic strokes; however, the clinical implication of a high prevalence of silent stroke is limited \[[@b51-jos-2017-02810]\]. However, the high prevalence of silent stroke in HF might be an indirect evidence that HF creates a stroke-prone environment and is likely to contribute to cognitive impairments, which are common in patients with HF \[[@b19-jos-2017-02810]\].

In summary, patients with HF often have many risk factors for stroke, such as AF, and HF itself also increases the stroke risk. For these reasons, patients with HF have a greater incidence of stroke than the general population. Furthermore, the prognosis after stroke is worse in the presence of HF than in the absence of HF. Given this relationship between HF and stroke, a new approach to stroke prevention in patients with HF is needed.

Brain injury resulting from HF
------------------------------

In addition to stroke, brain injury is increasingly recognized as a common adverse consequence of HF, of which cognitive impairment is well known \[[@b57-jos-2017-02810],[@b58-jos-2017-02810]\]. Cognitive impairment in HF includes attention and learning deficits, reduced psychomotor speed, diminished executive function, specific subtypes of memory dysfunctions, and to a lesser degree, language impairment and reduced visuospatial performance \[[@b57-jos-2017-02810],[@b59-jos-2017-02810],[@b60-jos-2017-02810]\]. After adjustment for age, socioeconomic status, and education, worse cognitive performances were reported in HF, which was observed not only in decompensated patients but also in stable patients \[[@b57-jos-2017-02810],[@b59-jos-2017-02810]-[@b61-jos-2017-02810]\]. Patients with HF also showed worse cognitive performances than patients with comorbidities, such as hypertension or ischemic heart disease \[[@b59-jos-2017-02810],[@b62-jos-2017-02810]\]. Although only a few studies investigated cognitive impairment according to the systolic function, one study showed that patients with HFrEF scored poorly on visuospatial/executive function, language domain, and attention domain, whereas those with HFpEF scored poorly on delayed recall and abstraction domain \[[@b63-jos-2017-02810]\]. The severity of HF was related to the increased risk of cognitive impairments, and HF treatment may improve patients' cognition \[[@b58-jos-2017-02810],[@b64-jos-2017-02810]\].

Several studies have reported structural changes, such as gray matter atrophy and white matter hyperintensities, in HF \[[@b53-jos-2017-02810],[@b59-jos-2017-02810]\]. These changes were also observed in stable as well as in decompensated patients. Interestingly, in these studies, cortical gray matter loss in HF suggests that mechanisms other than hypoperfusion are involved in brain injury, as the vasculature is rich in the cortical gray matter \[[@b57-jos-2017-02810],[@b59-jos-2017-02810]\].

It is thought that various factors cause brain injury in HF. One of the most well-known mechanisms for brain injury in HF is diminished cerebral blood flow \[[@b57-jos-2017-02810]\]. In addition, changes in neurohormones, such as cortisol and catecholamine; inflammatory responses associated with myocardial injury; and nutritional deficiency, such as thiamine deficiency, are known to cause brain injury in HF \[[@b57-jos-2017-02810]\].

Mechanism of stroke in HF
=========================

Traditionally, the following are the known causes of ischemic stroke: (1) embolism to the brain of cardiac or aortic origin (i.e., myocardial infarction, AF, valvular heart disease, complicated aortic plaque, or patent foramen ovale); (2) cerebral ischemia due to perfusion failure and artery-to-artery embolism (i.e., large artery atherosclerotic plaque, small vessel disease or occlusion, or vasculitis); and (3) thrombosis (prothrombotic state) \[[@b65-jos-2017-02810]\]. Not surprisingly, HF comprises all of these. Therefore, to elucidate the mechanism of stroke in HF, either thromboembolism or hypoperfusion should be explained.

Thromboembolism
---------------

Stroke in HF is thought to be caused mostly by a thromboembolic etiology \[[@b66-jos-2017-02810]\]. Approximately 150 years ago, three conditions (Virchow's triad: abnormalities of the blood flow, vessel wall, and blood constituents) were mentioned as prerequisites for thrombogenesis. Not surprisingly, patients with HF, particularly HFrEF, have all three conditions \[[@b67-jos-2017-02810]\].

First, akinetic ventricular segments and dilated left atrium or ventricle with stasis of the blood flow seen in HF may increase thrombus formation via a mechanism similar to that of AF (blood flow abnormalities) \[[@b68-jos-2017-02810]-[@b72-jos-2017-02810]\]\]. To demonstrate that HF itself can cause stroke, it is necessary to explain that such thromboembolisms can occur in HF without AF or systolic dysfunction. Therefore, much research has been conducted on the remaining prerequisites, such as abnormalities of the vessel walls and blood constituents in addition to the first prerequisite of the Virchow's triad, "stasis."

Second, patients with HF are in the prothrombotic state (abnormal blood constituents) \[[@b73-jos-2017-02810]-[@b84-jos-2017-02810]\]. The prothrombotic state of HF was supported by the observation of platelet hyperactivity, increased thrombin generation, and impaired fibrinolysis \[[@b74-jos-2017-02810],[@b82-jos-2017-02810],[@b85-jos-2017-02810]\]. This prothrombotic state was further enhanced by the activated sympathetic nervous system and renin-angiotensin-aldosterone system and by systemic inflammation, which are the characteristics of HF \[[@b74-jos-2017-02810],[@b82-jos-2017-02810],[@b86-jos-2017-02810]\]. These prothrombotic trends were also found in HFpEF \[[@b73-jos-2017-02810]\]; thus, the thrombotic profile in HF was observed regardless of systolic dysfunction.

Third, there are functional and/or structural damages in the blood vessels due to endothelial dysfunction or atherosclerosis in HF (vessel wall abnormalities) \[[@b81-jos-2017-02810],[@b82-jos-2017-02810],[@b87-jos-2017-02810]\]. In a defective endothelium, the release of endothelium-derived nitric oxide in response to stimuli is impaired, which, in turn, may promote monocyte and platelet adhesion to the endothelium, leading to thrombosis and thromboembolism \[[@b67-jos-2017-02810]\]. In addition, the level of von Wille-brand factor, a marker that reflects endothelial damage or dysfunction, is abnormally high in HF, which appears to be involved in making a hypercoagulable state in HF \[[@b81-jos-2017-02810],[@b82-jos-2017-02810],[@b85-jos-2017-02810]\].

Hypoperfusion
-------------

Contemporary data have shown that the cerebral blood flow can be abnormal in HF \[[@b57-jos-2017-02810]\]. The "hypoperfused" state in HF is explained by a low cardiac output as well as a compromised autoregulation \[[@b88-jos-2017-02810],[@b89-jos-2017-02810]\]. In HF, carbon dioxide levels fluctuate, and cerebrovascular reactivity, a response of cerebral vasculature to high carbon dioxide levels, is also abnormal \[[@b88-jos-2017-02810],[@b90-jos-2017-02810],[@b91-jos-2017-02810]\]. In this hypoperfused condition, specific areas of the brain that are supplied by the deep penetrating arteries, lack collateral flow, or are located at the junction supplied by the anterior, middle, or posterior cerebral artery are vulnerable to ischemic damage.

Based on the increased arterial stiffness and reduced vasodilatory reserve in HFpEF \[[@b92-jos-2017-02810]\], it may be assumed that the cerebral blood flow has also decreased in HFpEF. However, no study has investigated how the cerebral blood flow changes in HFpEF.

Atherosclerosis
---------------

In a cohort study of acute stroke \[[@b93-jos-2017-02810]\], the mechanism of stroke in patients with HF but without AF was associated with the etiology of HF. According to this study, valvular heart disease and dilated cardiomyopathy were mainly associated with cardioembolic stroke, whereas HF due to coronary artery disease or hypertension was mainly associated with atherosclerotic and lacunar strokes, respectively. Considering that coronary heart disease is the main cause of HF \[[@b94-jos-2017-02810]-[@b97-jos-2017-02810]\], followed by hypertension and diabetes, atherosclerosis is also thought to contribute to stroke development in patients with HF.

Stroke prevention in patients with HF
=====================================

Current guidelines and previous studies
---------------------------------------

### HF with AF

The use of non-vitamin K antagonist oral anticoagulant (NOAC) as well as warfarin in patients with AF has been extensively studied. The current guidelines recommend assessing stroke risks in patients with AF using the CHA~2~DS~2~-VASc scoring system \[[@b98-jos-2017-02810],[@b99-jos-2017-02810]\]. In both the American College of Cardiology/American Heart Association and European Society of Cardiology guidelines, oral anticoagulation is strongly recommended for patients with a CHA~2~DS~2~-VASc score of 2 or more \[[@b98-jos-2017-02810],[@b99-jos-2017-02810]\]. In the case of a CHA~2~DS~2~-VASc score of 1, the American guideline permits all three options (no antithrombotic treatment, oral anticoagulant, or aspirin) \[[@b99-jos-2017-02810]\]. However, the more recently published European guideline recommends the use of oral anticoagulation as class IIa with level of evidence B, as there is a growing evidence in which oral anticoagulants may be beneficial in men with a CHA~2~DS~2~-VASc score of 1 and in women with a CHA~2~DS~2~-VASc score of 2 \[[@b98-jos-2017-02810]\]. As the CHA~2~DS~2~-VASc score is at least 1 in patients with HF, an anticoagulation in those with HF and AF should be considered. In patients with contraindications to anticoagulants, such as high bleeding risks, left atrial appendage occlusion may be considered as class IIb with level of evidence B \[[@b98-jos-2017-02810]\].

### HF without AF

There have been four trials (Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction \[WARCEF\], Warfarin and Antiplatelet Therapy in Chronic Heart Failure \[WATCH\], Heart Failure Long-term Antithrombotic Study \[HELAS\], and Warfarin/Aspirin Study in Heart Failure \[WASH\]) of stroke prevention in patients with HFrEF who maintained sinus rhythm. In the WASH and HELAS trials, there was no significant difference between patients receiving warfarin, aspirin, and placebo at the composite endpoint of death, stroke, or myocardial infarction \[[@b100-jos-2017-02810],[@b101-jos-2017-02810]\]. However, these trials included a small cohort. The WATCH trial, which had a larger cohort than the WASH trial, showed that the incidence of ischemic stroke was further reduced with warfarin compared to aspirin or clopidogrel. However, the primary composite outcome of all-cause mortality, nonfatal myocardial infarction, and nonfatal stroke was neutral among the three antithrombotic groups \[[@b102-jos-2017-02810]\]. In the WARCEF trial, which was the most recent and largest study among the four trials, the incidence of ischemic stroke was lower with warfarin than with aspirin (0.72 events per 100 patient-years vs. 1.36 per 100 patient-years; HR, 0.52; 95% CI, 0.33 to 0.82); however, the benefit was counteracted by an increase in major bleeding events (1.78 events per 100 patient-years vs. 0.87 per 100 patient-years; HR, 2.05; 95% CI, 1.36 to 3.12) \[[@b103-jos-2017-02810]\]. A meta-analysis of these four trials showed that stroke prevention using warfarin was evident in these patients \[[@b104-jos-2017-02810]\]. In this analysis, oral anticoagulation using warfarin reduced the stroke risk by 41 compared with that using aspirin. However, the risk of bleeding doubled, which offset the benefits of stroke prevention. Furthermore, there was no difference in the mortality rate, incidence rate of myocardial infarction, and hospitalization rate between the groups.

Although no study has investigated anticoagulation for stroke prevention, specifically in patients with HFpEF but without AF, a real-world cohort study with incident HF cases excluding AF showed a significant reduction in the composite of death or all strokes with warfarin use \[[@b22-jos-2017-02810]\]. However, the result was limited by the absence of data to confirm the proportions with HFpEF or HFrEF. Further studies targeting patients with HFpEF but without AF for stroke prevention are needed.

Based on the results of previous studies, the use of warfarin for the prevention of stroke in patients with sinus rhythm seems to be beneficial at least in HFrEF. However, the routine use of warfarin in patients with HFrEF but without AF appears to be limited, as benefits are offset by the risk of bleeding. This suggests two possibilities. First, anticoagulation may be beneficial only for certain patients with a higher stroke risk beyond bleeding risk. Therefore, the adequate stratification of patients with a high stroke risk may be important. Second, the use of oral anticoagulants can be justified if the anticoagulants have a broad spectrum of safety profile with a lower bleeding risk. Because of this, NOACs are expected to be a treatment option for stroke prevention in HF in the future.

Risk stratification
-------------------

There is a continuing need for a simple clinical model to predict the stroke risk in patients with HF. Several attempts have been made to predict patients with a high stroke risk. However, no satisfactory model has yet been developed.

### Predictors of stroke in patients without AF

In a previous study analyzing the risk of stroke in patients with HF but without AF \[[@b37-jos-2017-02810]\], several variables were reported to be associated with stroke. The authors identified five independent predictors of stroke in patients with HFrEF but without AF (ranked by the χ^2^ value): (1) age (HR, 1.34; 95% CI, 1.18 to 1.63 per 10 years); (2) New York Heart Association (NYHA) class (HR, 1.60; 95% CI, 1.21 to 2.12 class III/IV vs. II); (3) diabetes mellitus treated with insulin (HR, 1.87; 95% CI, 1.22 to 2.88); (4) body mass index (HR, 0.74; 95% CI, 0.60 to 0.91 per 5 kg/m^2^ up to 30); and (5) previous stroke (HR, 1.81; 95% CI, 1.19 to 2.74). With a risk score formulated from these predictors using the coefficients for each variable, patients in the top third of this score had a rate of stroke that approximated the risk in patients with AF ([Table 1](#t1-jos-2017-02810){ref-type="table"}). The overall c-index for this "stroke risk score" model was 0.75 (95% CI, 0.62 to 0.86). These results were consistent with those for patients with HFpEF but without AF \[[@b36-jos-2017-02810]\]. This scoring system should be tested prospectively in a randomized trial.

### CHADS~2~ score

The CHADS~2~ score and CHA~2~DS~2~-VASc score are known to be useful methods for stratifying stroke risks in patients with AF. Kondo et al. \[[@b105-jos-2017-02810]\] compared the aforementioned "stroke risk score" \[[@b37-jos-2017-02810]\] with the CHADS~2~ and CHA~2~DS~2~-VASc scores to predict stroke in patients with HFrEF but without AF. In this study, the CHADS~2~ and CHA~2~DS~2~-VASc scores (c-index, 0.794; 95% CI, 0.663 to 0.925 vs. c-index, 0.740; 95% CI, 0.605 to 0.875, respectively), but not the "stroke risk score" (c-index, 0.625; 95% CI, 0.488 to 0.762), were still significantly associated with ischemic stroke \[[@b105-jos-2017-02810]\]. In terms of the discriminatory ability for ischemic stroke, the CHADS~2~ score had the highest area under the curve (0.805; 95% CI, 0.719 to 0.892). In this study, the cohort size of patients with severe symptoms (NYHA III or IV) or diabetes mellitus treated with insulin was smaller than that in the previous study using the "stroke risk score." Thus, it is difficult to evaluate it accurately. However, the possibility of the CHADS~2~ score or CHA~2~DS~2~-VASc score as a stroke risk model in patients with HFrEF but without AF was suggested.

### CHA~2~DS~2~-VASc score

It has been suggested in some studies that CHA~2~DS~2~-VASc score, which was applied to patients with AF, may be useful for stratifying the stroke risk when applied to patients with HF but without AF \[[@b32-jos-2017-02810],[@b106-jos-2017-02810]\], or even to the general population \[[@b32-jos-2017-02810]\].

In a Danish cohort study \[[@b106-jos-2017-02810]\], CHA~2~DS~2~-VASc score was first used to predict ischemic stroke in patients with incident HF. In particular, the risk of ischemic stroke increased with a clear dose-response relationship as the score increased at high CHA~2~DS~2~-VASc scores (≥4), regardless of AF. The discriminatory ability of CHA~2~DS~2~-VASc score was moderate, although it varied depending on the presence of AF and duration of follow-up (c-index, 0.64 to 0.71). Because of its modest predictive accuracy, the use of CHA~2~DS~2~-VASc score for stroke risk stratification may be limited in clinical practice. However, it was suggested that CHA~2~DS~2~-VASc score could be a useful tool for identifying "low-stroke risk" patients because CHA~2~DS~2~-VASc score yielded a high negative predictive value (92%; 95% CI, 91 to 93) for ischemic stroke at the 1-year follow-up. Identification of patients at a "truly low" risk would be important especially because they are less likely to benefit from anticoagulation.

Recently, the use of CHA~2~DS~2~-VASc score was more extended. In a Korean cohort study, as the score increased, the incidence of stroke also increased across all groups studied: general control population; HF without AF group; AF without HF group; and HF with AF group \[[@b32-jos-2017-02810]\]. Although the HF without AF group had a slightly lower overall stroke rate than the AF without HF group, the stroke risk was comparable in both groups when the patients were stratified by CHA~2~DS~2~-VASc scores \[[@b32-jos-2017-02810]\]. These results suggest that we may stratify patients with HF at a high risk of stroke who are more likely to benefit from anticoagulation.

Although the abovementioned studies support the usefulness of CHA~2~DS~2~-VASc score in patients with HF, those studies were unable to distinguish between HFpEF and HFrEF.

In the CHADS~2~ or CHA~2~DS~2~-VASc scoring system, not all individual components were established as risk factors of ischemic stroke in the HF population. Previous studies on patients with HF have reported that some of these components may not be related to (e.g., age of \>75 years, female sex, hypertension, diabetes, and vascular disease) \[[@b6-jos-2017-02810],[@b22-jos-2017-02810]\] or may even reduce (e.g., female sex) \[[@b107-jos-2017-02810]\] the stroke risk. Therefore, studies on the stroke risk of each component are also necessary. In addition, the abovementioned "stroke risk score" and CHADS~2~ score or CHA~2~DS~2~-VASc score commonly includes age, diabetes, and prior stroke. Therefore, the stroke risk is expected to increase at least in patients with HF with these components.

### Time variable

Many reports have described the risk of stroke to be much higher in the initial period following incident HF \[[@b6-jos-2017-02810],[@b20-jos-2017-02810],[@b22-jos-2017-02810],[@b23-jos-2017-02810]\]. Compared with the data of the general population, data from a recent Danish nationwide registry indicated a 5-fold elevated 30-day ischemic stroke risk after first-time hospitalization for HF \[[@b20-jos-2017-02810]\]. It remained elevated for over 30 years (2-fold increase between 31 and 365 days and 1.5-fold increase between 1 and 30 years). In another community-based study, HF was associated with a 17-fold increased risk for ischemic stroke compared with that in the general population in the first 30 days after HF diagnosis \[[@b6-jos-2017-02810]\]. Furthermore, the risk persisted for over 5 years. The Danish Diet, Cancer and Health Cohort study showed again that the risk of ischemic stroke is time dependent \[[@b22-jos-2017-02810]\]. While it was lower than the 30-day risk, the higher risk was not normalized 6 months after the diagnosis of incident HF. Similarly, in a Dutch cohort study, the risk of ischemic stroke increased by 4.6-fold in the first 30 days after HF diagnosis \[[@b23-jos-2017-02810]\]. Although it remains uncertain whether the ischemic stroke risk returns to the baseline values over time owing to inconsistent findings in previous studies \[[@b6-jos-2017-02810],[@b20-jos-2017-02810],[@b22-jos-2017-02810],[@b23-jos-2017-02810]\], these studies have consistently demonstrated an increased risk of ischemic stroke in the first 30 days after the HF diagnosis. These results suggest that there might be a more efficient period for stroke prevention, albeit this hypothesis needs to be confirmed.

Taken together, anticoagulation for stroke prevention might be considered for patients with HF at a high risk based on several variables (e.g., age, diabetes, and prior stroke), especially within the first month after the diagnosis of HF. Further studies are needed to develop a clinical model to predict the stroke risk in patients with HF, including variables, such as time interval following the diagnosis of incident HF.

In the era of NOACs
-------------------

NOACs, including dabigatran, rivaroxaban, apixaban, and edoxaban, have been approved by the Food and Drug Administration based on their respective clinical trials \[[@b108-jos-2017-02810]-[@b112-jos-2017-02810]\]. Sub-group analyses of these studies showed that NOACs were effective and safe in patients with HF and AF similar to warfarin ([Table 2](#t2-jos-2017-02810){ref-type="table"}) \[[@b113-jos-2017-02810]-[@b117-jos-2017-02810]\]. Although there was no significant benefit in individual trials, a recent meta-analysis showed that NOACs could be better than warfarin with regard to their efficacy and safety \[[@b118-jos-2017-02810]\]. This meta-analysis showed that single-/high-dose NOACs in patients with AF and HF decreased the number of stroke/systemic embolic events by 14% (OR, 0.86; 95% CI, 0.76 to 0.98) and major bleeding events by 24% (OR, 0.76; 95% CI, 0.67 to 0.86), as compared with warfarin \[[@b118-jos-2017-02810]\]. Although clinical trials of conventional antithrombotic therapies for patients with HF but without AF failed to show a clinical benefit, NOACs might yield some differences.

In general, compared with warfarin, NOACs have rapid onset and offset of action, yield more predictable anticoagulant responses, and can be administered at fixed doses without routine monitoring, thereby simplifying therapy \[[@b119-jos-2017-02810]\]. In addition, dietary vitamin K intake does not affect NOACs; therefore, dietary restrictions are not required \[[@b119-jos-2017-02810]\]. There are also few clinically important drug-to-drug interactions with NOACs. This profile of NOACs can be an advantage for patients with HF who often take polypharmacy \[[@b97-jos-2017-02810]\] and have a high bleeding risk due to comorbidity. Conversely, NOACs are more dependent on the kidney for excretion than warfarin \[[@b119-jos-2017-02810]\]. Therefore, in patients with renal impairments, NOACs can potentially increase their bleeding risk, and their use is limited.

Because NOACs have been shown to be safe and effective for stroke prevention in patients with AF and HF, their safety and efficacy might be maintained in patients with HF but without AF. The Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51 (ATLAS ACS 2-TIMI 51) trial raised the possibility of the clinical benefit of anticoagulation using NOACs in patients with HF \[[@b120-jos-2017-02810]\]. The ATLAS ACS 2-TIMI 51 trial was originally attempted to evaluate the effect of low-dose rivaroxaban in patients with acute coronary syndrome (ACS). In an unpublished subgroup analysis (Janssen Research & Development LLC, Raritan, NJ, USA) \[[@b121-jos-2017-02810]\], rivaroxaban 2.5 mg twice daily reduced the incidence rates of cardiovascular death, myocardial infarction, and stroke (18.6% placebo vs. 11.6% rivaroxaban, *P*\<0.001) as well as the all-cause mortality rate (11.1% placebo vs. 5.3% rivaroxaban, *P*\<0.001) in patients with HF at the time of ACS. These results from the ATLAS ACS 2-TIMI 51 trial led to a randomized clinical trial using NOACs in patients with HF and sinus rhythm. The Coronary Artery Disease Following an Episode of Decompensated Heart Failure (COMMANDER HF) trial is currently investigating the efficacy and safety of rivaroxaban (2.5 mg twice daily) in reducing the risk of stroke, myocardial infarction, or even death compared with placebo in patients with HFrEF, without AF, but with a significant coronary artery disease \[[@b121-jos-2017-02810]\].

Conclusions
===========

Stroke and HF are frequently occurring adverse events that are associated with high mortality and morbidity rates. Although AF, which develops in more than half of patients with HF, is a major risk factor for stroke, the role of HF itself as a risk factor for stroke has been underestimated. There is a growing evidence that HF itself increases the risk of stroke regardless of AF through various mechanisms, mainly by thromboembolism. However, previous studies have failed to show the benefit of warfarin in patients with HF but without AF, as the benefit of stroke prevention was counteracted by the increased incidence of major bleeding. Recently, studies have been conducted to identify patients with HF at a high stroke risk who may benefit more from anticoagulation. Based on the stroke risk prediction model, it may be plausible to select the best strategy to prevent stroke in patients with HF. Moreover, NOACs, which provide a favorable risk-benefit profile compared with warfarin, are an attractive therapeutic option.

Thus, the use of NOACs can be an effective stroke prevention strategy in patients with HF, especially in those at a high stroke risk as well as in those in the period of a high stroke risk. This outlook needs to be proven in further studies.
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###### 

Annual stroke risk (%/year) stratified by type of heart failure, presence of AF and anticoagulant use (if AF present)

                                                                                                                             Without AF (%/yr)   With AF (%/yr)   Reference                                                   
  -------------------------------------------------------------------------------------------------------------------------- ------------------- ---------------- ----------------------------------------------------- ----- ----
  HFrEF^[\*](#tfn1-jos-2017-02810){ref-type="table-fn"}^ (high risk group)^[†](#tfn2-jos-2017-02810){ref-type="table-fn"}^   1.2 (2.0)           1.6              1.2^[‡](#tfn3-jos-2017-02810){ref-type="table-fn"}^   2.2   37
  HFpEF^[§](#tfn4-jos-2017-02810){ref-type="table-fn"}^ (high risk group)^[†](#tfn2-jos-2017-02810){ref-type="table-fn"}^    1.0 (1.6)           1.8              1.5                                                   2.2   36

AF, atrial fibrillation; HFrEF, heart failure with reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction.

From the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza cardiaca-Heart Failure (GISSI-HF) trials;

According to the author's specific model for stroke based on clinical variables such as previous stroke, diabetes treated with insulin, age, body mass index and New York Heart Association functional class;

Estimated from the analysis of reference 37;

From the Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity-Preserved (CHARM-Preserved) trial and the Irbesartan in Heart Failure with Preserved Systolic Function trial (I-Preserve) trial.

###### 

Subgroup analysis of patients with heart failure in pivotal studies of non-vitamin K antagonist oral anticoagulants

  Study                                                                Design                                         Definition of HF                                                                                                                           NOAC vs. warfarin                                                                                                                                                                                                                                                               
  -------------------------------------------------------------------- ---------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ ------------------- ------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ------------------- ------
  RE-LY^[†](#tfn6-jos-2017-02810){ref-type="table-fn"}^ (Dabigatran)   HF (n=4,904, 27%)                              NYHA class II or higher HF symptoms in the 6 months before screening, in patients with a history of previous admission for congestive HF   1.44                1.92                0.75 (0.51--1.10)                                    0.39                                                 3.10                                                 3.90                                                 0.79 (0.60--1.03)   0.16
  No HF (n=13,209, 73%)                                                1.00                                           1.64                                                                                                                                       0.61 (0.47--0.79)                       3.39                                                 3.45                                                 0.99 (0.84--1.16)                                                                                                             
  ROCKET-AF (Rivaroxaban)                                              HF (n=9,033, 64%)                              Prior history of HF or a left ventricular EF \<40%                                                                                         1.90                2.09                0.91 (0.74--1.13)                                    0.62                                                 NA^[‡](#tfn7-jos-2017-02810){ref-type="table-fn"}^   NA^[‡](#tfn7-jos-2017-02810){ref-type="table-fn"}^                       
  No HF (n=51,380, 36%)                                                2.10                                           2.54                                                                                                                                       0.84 (0.65--1.09)                       NA^[‡](#tfn7-jos-2017-02810){ref-type="table-fn"}^   NA^[‡](#tfn7-jos-2017-02810){ref-type="table-fn"}^                                                                                                                                 
  ARISTOTLE (Apixaban)                                                 LVSD (n=2,736, 19%)                            EF ≤40% or report of moderate or severe LVSD                                                                                               0.99                1.80                0.55 (0.34--0.91)                                    0.21                                                 2.77                                                 3.41                                                 0.81 (0.58--1.14)   0.50
  HFpEF (n=3,207, 22%)                                                 EF \>40% or normal LV function, or mild LVSD   1.51                                                                                                                                       1.54                0.98 (0.65--1.49)                                                        1.95                                                 3.17                                                 0.62 (0.44--0.88)                                                        
  No HF (n=8,728, 59%)                                                 Neither LVSD nor HFpEF                         1.16                                                                                                                                       1.58                0.74 (0.57--0.96)                                                        2.17                                                 2.83                                                 0.77 (0.62--0.94)                                                        
  ENGAGE-AF (Edoxaban)                                                 HF NYHA I--II (n=6,344, 45%)                   Presence or previous history of HF stage C or D according to the American College of Cardiology/American Heart Association definition      1.52                1.73                0.88 (0.69--1.12)                                    0.97                                                 2.61                                                 3.31                                                 0.79 (0.65--0.96)   0.96
  HF NYHA III--IV (n=1,801, 13%)                                       1.83                                           2.18                                                                                                                                       0.83 (0.55--1.25)                       2.49                                                 3.17                                                 0.79 (0.54--1.17)                                                                                                             
  No HF (n=5,926, 42%)                                                 1.54                                           1.77                                                                                                                                       0.87 (0.69--1.11)                       2.98                                                 3.63                                                 0.82 (0.68--0.99)                                                                                                             

Adapted from Isnard et al. \[[@b117-jos-2017-02810]\]

HF, heart failure; NOAC, non-vitamin K antagonist oral anticoagulants; HR, hazard ratio; CI, confidence interval; RE-LY, Randomised Evaluation of Long-Term Anticoagulation Therapy; NYHA, New York Heart Association; ROCKET-AF, Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; EF, ejection fraction; NA, not available; ARISTOTLE, Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; LVSD, left ventricular systolic dysfunction; HFpEF, heart failure with preserved ejection fraction; LV, left ventricular; ENGAGE-AF, Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation.

*P*-value for interaction;

For RE-LY study, only results for Dabigatran 150 mg are reported in this table;

For ROCKET study, the primary safety endpoint was major or non-major clinically relevant bleeding.
